Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicole J Gormley

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Critical Care Medicine|September 20, 2011
The rising incidence of intentional ingestion of ethanol-containing hand sanitizersNicole J Gormley, Alvin C Bronstein, Joseph J Rasimas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2017
FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaNicole J Gormley, Chia-Wen Ko, Albert Deisseroth, et al.
Cytometry. Part B, Clinical Cytometry|June 26, 2015
Regulatory perspective on minimal residual disease flow cytometry testing in multiple myelomaNicole J Gormley, Danielle M Turley, Jennifer S Dickey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell LymphomasMaryam Sarraf Yazdy, Yvette L Kasamon, Wenjuan Gu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2021
Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025Peter M Voorhees, Andrzej J Jakubowiak, Shaji K Kumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2024
FDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple MyelomaAndrea C Baines, Bindu Kanapuru, Jay Zhao, et al.
The Oncologist|June 16, 2021
FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell LymphomaYvette L Kasamon, Lauren S L Price, Olanrewaju O Okusanya, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 3, 2023
The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990-2018Nadia Howlader, Elad Sharon, Manami Bhattacharya, et al.
The Oncologist|September 15, 2017
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior TherapyVishal Bhatnagar, Nicole J Gormley, Lola Luo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2023
Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA PerspectiveAndrea C Baines, Maryam Sarraf Yazdy, Yvette L Kasamon, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Critical Care Medicine|September 20, 2011
The rising incidence of intentional ingestion of ethanol-containing hand sanitizersNicole J Gormley, Alvin C Bronstein, Joseph J Rasimas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2017
FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaNicole J Gormley, Chia-Wen Ko, Albert Deisseroth, et al.
Cytometry. Part B, Clinical Cytometry|June 26, 2015
Regulatory perspective on minimal residual disease flow cytometry testing in multiple myelomaNicole J Gormley, Danielle M Turley, Jennifer S Dickey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell LymphomasMaryam Sarraf Yazdy, Yvette L Kasamon, Wenjuan Gu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2021
Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025Peter M Voorhees, Andrzej J Jakubowiak, Shaji K Kumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2024
FDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple MyelomaAndrea C Baines, Bindu Kanapuru, Jay Zhao, et al.
The Oncologist|June 16, 2021
FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell LymphomaYvette L Kasamon, Lauren S L Price, Olanrewaju O Okusanya, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 3, 2023
The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990-2018Nadia Howlader, Elad Sharon, Manami Bhattacharya, et al.
The Oncologist|September 15, 2017
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior TherapyVishal Bhatnagar, Nicole J Gormley, Lola Luo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2023
Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA PerspectiveAndrea C Baines, Maryam Sarraf Yazdy, Yvette L Kasamon, et al.
Pageof 2